Unveiling the Power of ALAUNOS Therapeutics: A Look into their Revolutionary HUNTR TCR Discovery Platform at the Society for Immunotherapy of Cancer’s 2022 Annual Meeting
Alaunos Therapeutics to Present Data High… Data supports high-throughput screening process to identify neoantigen-reactive TCRs Exclusive ownership of discovered KRAS mutation-reactive TCRs hunTR enables expansion of the Company’s hotspot mutation targeted TCR library HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company…